Muscle Loss in Women: What Could Be Causing It and What to Do Next

Why Muscle Loss Hits Women Differently Than Men

Women start with less skeletal muscle mass than men, on average, and face a more abrupt hormonal transition that accelerates its loss. This is not a minor physiological footnote. It changes how you interpret symptoms, what labs to order, and which interventions actually work.

Skeletal muscle is metabolically active tissue. It regulates blood sugar, supports bone density, drives resting energy expenditure, and protects against falls. When you lose it, the downstream effects include weight gain despite unchanged eating, worsening insulin resistance, increased fracture risk, and fatigue that no amount of sleep fixes.

The Estrogen Connection

Estrogen receptors sit on skeletal muscle cells. Estrogen signals muscle protein synthesis, reduces inflammation-driven muscle breakdown, and supports satellite cell activity (the repair mechanism that rebuilds damaged fibers after exercise). When estrogen falls, all three processes slow ncbi.nlm.nih.gov.

This is why perimenopause, which can begin in the early 40s, is often the first time women notice visible muscle changes even when their exercise habits haven't changed. The transition is not sudden, but the loss is real and measurable.

How Progesterone and Testosterone Factor In

Progesterone is catabolic in high doses and may counteract some of estrogen's muscle-preserving effects in the luteal phase. Testosterone, though present in smaller amounts in women than in men, plays a direct anabolic role. Women with primary ovarian insufficiency, post-surgical menopause, or adrenal insufficiency often have lower free testosterone and show faster lean mass decline pubmed.ncbi.nlm.nih.gov.

The Most Common Causes of Muscle Loss in Women, by Life Stage

Muscle loss is a symptom, not a diagnosis. The differential is wide, and life stage narrows it substantially.

Reproductive Years (roughly ages 20-40)

Relative Energy Deficiency in Sport (RED-S). This is the modern framework replacing the "female athlete triad." RED-S occurs when caloric intake is chronically insufficient relative to energy expenditure, regardless of athletic identity. You don't have to be a competitive athlete for this to apply. Women on aggressive calorie deficits, those with a history of restrictive eating, or women doing high-volume exercise without adequate fueling are all at risk. Muscle catabolism accelerates as the body prioritizes fuel for critical organ function pubmed.ncbi.nlm.nih.gov.

PCOS. Polycystic ovary syndrome affects an estimated 10-13% of women of reproductive age. The insulin resistance central to PCOS impairs muscle protein synthesis. Higher androgen levels in PCOS are sometimes thought to be protective of muscle, but the metabolic dysfunction often outweighs this. Women with PCOS who are sedentary or in caloric deficit can lose lean mass while simultaneously gaining fat mass, a pattern sometimes called "body recomposition in reverse."

Thyroid dysfunction. Both hypothyroidism and hyperthyroidism cause muscle changes, but through different mechanisms. Hypothyroidism slows protein turnover and can cause myopathy; hyperthyroidism accelerates catabolism. Hashimoto thyroiditis, which affects women at roughly 7-10 times the rate of men, is the most common cause of hypothyroidism in the developed world and a frequently missed contributor to muscle loss.

Postpartum and Lactation

Postpartum muscle loss is under-discussed and under-studied. Women may lose 3-5 kg of lean mass in the first year postpartum, particularly those who are breastfeeding while restricting calories to lose pregnancy weight pubmed.ncbi.nlm.nih.gov. Sleep deprivation elevates cortisol, which is directly catabolic to muscle. Protein needs are elevated during lactation (approximately 1.3-1.7 g/kg/day by most estimates), and many postpartum women are not meeting baseline requirements, let alone the higher threshold.

The postpartum thyroid window also matters here. Postpartum thyroiditis affects approximately 5-10% of women in the first year after delivery. The hyperthyroid phase accelerates muscle catabolism; the subsequent hypothyroid phase causes fatigue and myopathy that many women attribute to early motherhood.

Perimenopause (typically ages 40-52)

This is the highest-risk window for accelerated muscle loss. Estrogen levels begin to fluctuate and decline erratically. One landmark analysis found that women lose an average of 0.5 kg of lean mass per year during the menopausal transition, with the steepest decline occurring in the two years surrounding the final menstrual period.

Cortisol sensitivity also changes in perimenopause. Women in this stage are more susceptible to stress-related muscle catabolism and recover more slowly from training. Sleep disruption from vasomotor symptoms compounds this, since growth hormone, which drives overnight muscle repair, is released primarily during deep sleep.

GLP-1 receptor agonists and muscle loss in perimenopause. This is increasingly relevant. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) cause significant weight loss, but clinical trial data from the STEP 1 trial show that approximately 39% of total weight lost on semaglutide is lean mass. In perimenopausal women who are already losing muscle from estrogen decline, this compound effect can be clinically significant. Adequate protein intake and resistance training are not optional add-ons for women on GLP-1 therapy in this life stage. They are the primary preservation strategy.

Post-Menopause

Sarcopenia, defined clinically as low muscle mass plus low muscle strength or physical performance, affects an estimated 10-40% of older women depending on diagnostic criteria. The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) revised its definition in 2019 to center strength, not just mass, as the primary marker.

Post-menopausal women have the lowest estrogen, the highest insulin resistance, and often the lowest protein intake. These three factors synergize to accelerate lean mass loss at a time when preserving it is most critical for fall prevention, fracture recovery, and metabolic health.

Medical Conditions That Cause Muscle Loss and Are Often Missed

Beyond hormonal drivers, several systemic conditions cause muscle loss in women and are worth ruling out.

Autoimmune and Inflammatory Disease

Rheumatoid arthritis, lupus, and inflammatory bowel disease all cause inflammatory muscle catabolism. TNF-alpha and IL-6, the cytokines elevated in chronic inflammation, directly inhibit muscle protein synthesis and accelerate breakdown. Women with these conditions often experience muscle loss independent of their activity level, and it worsens during disease flares.

Celiac Disease and Malabsorption

Undiagnosed celiac disease causes malabsorption of protein, iron, and B vitamins, all substrates for muscle synthesis. Women are diagnosed with celiac disease at roughly twice the rate of men, and many have subtle or non-GI presentations. If muscle loss accompanies bloating, unexplained anemia, or fatigue after gluten-containing meals, serum IgA anti-tissue transglutaminase antibody testing is appropriate.

Type 2 Diabetes and Insulin Resistance

Insulin is anabolic. When cells are insulin-resistant, the muscle-building signal from insulin is impaired even when circulating insulin levels are high. Women with type 2 diabetes show accelerated sarcopenia progression compared with metabolically healthy women of the same age. This creates a vicious cycle: muscle loss worsens insulin resistance, which worsens muscle loss.

Eating Disorder History

Women with a history of anorexia nervosa or prolonged caloric restriction may have permanently altered bone density and muscle architecture. The muscle loss from severe restriction is not always fully reversible with re-feeding, particularly when restriction occurred during peak bone and muscle mass development (ages 16-25). This history should be part of any intake evaluation.

Medications That Accelerate Muscle Loss

Several medications prescribed frequently to women affect lean mass:

• Glucocorticoids (prednisone, dexamethasone): directly catabolic; dose and duration matter
• Aromatase inhibitors (anastrozole, letrozole) used in breast cancer: block estrogen conversion and accelerate muscle loss alongside bone loss
• Depot medroxyprogesterone acetate (Depo-Provera): associated with body composition changes in some studies
• Statins: rare but real myopathy risk, more common in women than men pubmed.ncbi.nlm.nih.gov
• GLP-1 receptor agonists (semaglutide, tirzepatide): lean mass loss as part of total weight loss, as noted above

How Muscle Loss Is Diagnosed in Women

Diagnosis requires more than a visual assessment or subjective complaint.

Imaging and Physical Testing

DEXA (dual-energy X-ray absorptiometry) is the clinical standard for measuring lean mass. It is the same scan used for bone density and gives appendicular skeletal muscle mass (ASM), which is then indexed to height squared (ASM/ht²). The EWGSOP2 cutoff for low muscle mass in women is <5.5 kg/m².

Grip strength, measured with a handheld dynamometer, correlates strongly with overall muscle function and mortality outcomes. A grip strength of <16 kg in women is the EWGSOP2 threshold for probable sarcopenia pubmed.ncbi.nlm.nih.gov.

The 5-times sit-to-stand test and gait speed are used in clinical settings to assess functional muscle performance, particularly in post-menopausal women and those over 65.

Blood Work

There is no single definitive blood marker for muscle loss, but a useful panel includes:

• TSH and free T4 (thyroid function)
• Fasting glucose and HbA1c (insulin resistance)
• 25-hydroxyvitamin D (deficiency impairs muscle function)
• Serum albumin and prealbumin (protein status)
• Complete metabolic panel (kidney and liver function, both of which affect protein metabolism)
• Estradiol and FSH (if perimenopausal status is unclear)
• Anti-tTG IgA if celiac disease is suspected
• CRP and ESR if inflammatory disease is suspected

A practical diagnostic framework for the clinician reviewing muscle loss in women: tier the workup by life stage first. A 28-year-old with muscle loss and amenorrhea needs RED-S and thyroid evaluation before a DEXA. A 49-year-old with new-onset fatigue, changing body composition, and disturbed sleep needs FSH, estradiol, TSH, and a DEXA as first-line testing, not a generalized "wellness panel."

When to See a Doctor About Muscle Loss

Muscle loss that warrants urgent evaluation includes:

• Visible, rapid loss over weeks without a clear cause (could indicate malignancy, severe hyperthyroidism, or adrenal crisis)
• Muscle weakness with asymmetry or neurological symptoms (rule out myopathy or motor neuron disease)
• Muscle loss accompanied by difficulty swallowing, skin changes, or Raynaud phenomenon (connective tissue disease)
• Any muscle loss in a woman undergoing cancer treatment

Slower, gradual loss is more common and often hormonal or nutritional, but still warrants a workup rather than acceptance.

Treatment for Muscle Loss in Women: What the Evidence Actually Supports

Treatment depends on cause. Here are the interventions with the strongest data in women specifically.

Resistance Training

Progressive resistance training (PRT) is the single most effective intervention across every life stage. "Progressive" means increasing load over time. Two to three sessions per week targeting major muscle groups is the evidence-based minimum pubmed.ncbi.nlm.nih.gov. The LIFTMOR trial showed that high-intensity resistance training (two supervised sessions per week at approximately 80-85% of 1-rep max) produced significant gains in femoral neck bone density and muscle mass in post-menopausal women with osteoporosis or osteopenia, reversing the assumption that this population needed only low-impact exercise.

The timing relative to menstrual cycle phase can optimize gains in reproductive-age women. Strength and power adaptations are somewhat greater in the follicular phase (days 1-14), when estrogen is rising and muscle recovery is faster pubmed.ncbi.nlm.nih.gov.

Protein Intake, Adjusted by Life Stage

The RDA of 0.8 g/kg/day is insufficient for women trying to preserve or build muscle. Current evidence supports:

• Reproductive-age women: 1.2-1.6 g/kg/day
• Perimenopausal women: 1.4-1.7 g/kg/day (higher threshold due to anabolic resistance)
• Post-menopausal women: 1.6-2.0 g/kg/day pubmed.ncbi.nlm.nih.gov
• Postpartum and lactating women: 1.5-1.7 g/kg/day
• Women on GLP-1 medications: minimum 1.6 g/kg/day to mitigate lean mass loss

Leucine content of the protein source matters. Post-menopausal women have anabolic resistance, meaning a higher leucine threshold is needed to trigger muscle protein synthesis. Whey protein, eggs, and animal-source proteins tend to have higher leucine density than plant sources, though a well-planned plant-based diet can meet needs with attention to dose and distribution.

Hormone Therapy in Perimenopause and Post-Menopause

The Menopause Society (formerly NAMS) states that menopausal hormone therapy (MHT) is appropriate for healthy women under 60 or within 10 years of menopause onset for symptom management, and evidence supports a modest muscle-preserving effect. Estrogen therapy has been shown in randomized trials to reduce the rate of lean mass loss during the menopausal transition pubmed.ncbi.nlm.nih.gov.

MHT does not replace resistance training or adequate protein intake. It reduces the rate of loss; it does not reverse existing sarcopenia on its own.

Vitamin D and Creatine

Vitamin D deficiency (<20 ng/mL) impairs muscle fiber function, particularly type II (fast-twitch) fibers. Supplementation to achieve serum 25(OH)D of 40-60 ng/mL is reasonable where deficiency is confirmed pubmed.ncbi.nlm.nih.gov.

Creatine monohydrate (3-5 g/day) has growing evidence for muscle preservation in post-menopausal women specifically. A 2021 meta-analysis found that creatine supplementation combined with resistance training produced significantly greater improvements in lean mass and strength in older women compared with training alone pubmed.ncbi.nlm.nih.gov.

Treating the Underlying Cause

If thyroid dysfunction is present, optimizing TSH (targeting a TSH of approximately 1.0-2.5 mIU/L in most symptomatic women) is a prerequisite for muscle recovery. If celiac disease is confirmed, a strict gluten-free diet allows intestinal healing and restored protein absorption. If GLP-1 medication is driving lean mass loss, the protein and resistance training targets above are the primary mitigation, and dose timing or selection may be worth discussing with your prescriber.

Pregnancy, Postpartum, and Lactation: What Changes

This section applies specifically to women who are pregnant, trying to conceive, or breastfeeding.

During pregnancy, muscle mass redistribution is normal. Skeletal muscle may not change dramatically in the first two trimesters, but physical activity recommendations from ACOG support continued resistance training in uncomplicated pregnancies. Protein needs increase to approximately 1.1-1.5 g/kg/day in the second and third trimesters.

Medications for muscle loss or sarcopenia are not appropriate in pregnancy. Creatine supplementation has limited safety data in pregnancy and is not recommended. Testosterone therapy is absolutely contraindicated in pregnancy due to risk of virilization of a female fetus.

During lactation, protein needs are elevated. Resistance training is safe and encouraged postpartum once a woman has medical clearance (typically 6 weeks after vaginal delivery, longer after cesarean). High-intensity exercise does not meaningfully affect breast milk composition or infant acceptance of milk pubmed.ncbi.nlm.nih.gov.

GLP-1 medications (semaglutide, tirzepatide, liraglutide) are contraindicated in pregnancy and breastfeeding. If you are on a GLP-1 medication and become pregnant, contact your prescriber immediately. These medications should be stopped at least 2 months before a planned pregnancy attempt given their half-life and the absence of safety data in human pregnancy.

Who This Is Right for and Who Should Take a Different Approach

Women most likely to benefit from the resistance training plus protein protocol:

• Perimenopausal women noticing body composition shifts despite unchanged habits
• Post-menopausal women with confirmed low muscle mass or grip strength on testing
• Women on GLP-1 medications concerned about lean mass loss
• Postpartum women past 6-week clearance with persistent fatigue and weakness
• Women with PCOS and insulin resistance trying to improve body composition

Women who need a different or additional approach first:

• Anyone with active eating disorder behaviors (a higher-protein prescription alone is not the answer and may worsen disordered patterns)
• Women with active hyperthyroidism (exercise capacity is limited until thyroid function is controlled)
• Women with connective tissue disease or inflammatory myopathy (resistance training intensity needs to be adjusted during flares)
• Women on aromatase inhibitors for breast cancer (need oncology-informed exercise programming, as joint pain limits conventional PRT)